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Benchmark Project: Critical Pathway for Controlled Donor After Circulatory Death  
 Few people want to discuss their own deaths, much less what they are going to do with 
their bodies once their lives have ended.  It is a crucial conversation, and one that can save lives.  
Donation of one’s organs creates the potential for one of the most elusive gifts of all, more time.  
The gruesome fact is that there are more people in need of organ transplants than there are 
organs available.  When supply and demand become a life or death situation, it brings on a whole 
new view to the business of healthcare.  Temper that with the knowledge that living donors are 
not possible for all types of needed organs, and it becomes even more poignant.  An estimated 
113,000 Americans, 3,100 of whom are Ohioans, are in need of a life-saving transplant at this 
time (ODH, 2019).  An average of 20 people dies in the United States each day waiting for an 
organ that never arrives (ODH, 2019).  Every failed attempt to procure organs from a potential 
donor means up to a potential eight lives lost and fifty lives not improved (MedlinePlus, 2020).   
In that vein, the transplant community is seeking to expand all viable means of organ 
transplantation.  As a small subset of all donation after circulatory death donors, the Maastricht 
III classification, or controlled donation after circulatory death (cDCD) population is the most 
viable of all DCD donors.  It is thus an excellent population upon which to focus improvement 
efforts.  Though riddled with potential for ethical dilemma, it has promise to significantly 
improve this deficit of treatment (Daemen, Koostra, Wijnen, Yin, & Heineman, 1994; Evrard, 
2014).  This benchmark proposal seeks to resolve the current barriers in place for addressing this 
particular population through the veil of a Toledo, Ohio hospital, Trauma-level One hospital, as 
an ideal exemplar for the types of large hospitals which should receive this intensified focus 
(TJC, 2004).  It will serve as a template for expansion into similar hospitals in the United States 
struggling with the same issue. 
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Rationale  
ProMedica Toledo Hospital is a 700-plus bed, Trauma-One Level Hospital located in 
downtown Toledo, Ohio.  This is the primary acute care hospital for the region, and as a large 
hospital, is the prime location for organ procurement (OP) efforts for this region (TJC, 2004).  
This facility is suffering from several setbacks in this effort, however.  The staff has ethical 
concerns related to the potential for comfort care to hasten death, all levels of leadership have 
ethical concerns with the level of the organ procurement organization’s (OPO) and organ 
procurement coordinator’s (OPC) involvement in the pre-death care of potential cDCD donors, 
and there is little direction outside of the OPO on the best practices for the process of OD in this 
population.  This trifecta has converged into sufficient discomfort with the program to improve 
it.  With lives on the line, all good-faith efforts to create a structured, equitable and standardized 
system for the procurement of organs is the ethical and moral decision in this community.  To 
address this problem, the following PICO question was formed: In potential organ donors after 
circulatory death (P), does the utilization of an evidence-based critical pathway from 
identification of potential donor to organ procurement (I) versus no utilization of an evidence-
based critical pathway (C) increase the rate of organ procurement and the satisfaction of donor 
families with the donation process (O)?   
Literature Synthesis  
Critical Pathway 
The utilization of an evidence-based critical pathway (EBCP) in the management of a 
potential cDCD donor through the procurement of organs is a widely recommended means by 
which an evidence-based template for action may be applied to the real world setting of the 
acute-care hospital (CCM & ETA, 2017; IOM, 2000; TJC, 2004).  This is most readily achieved 
CDCD CRITICAL PATHWAY    
  4 
through the utilization of the EBCP created by five of the leading organizations within the 
transplant industry.  (See Appendix A.)  However, each hospital has unique barriers, cultures, 
and needs that must be addressed for such an EBCP to work.  This EBCP addresses much of the 
federal requirements, but cannot meet the needs of each individual state and regional needs 
within one document.  Thus, the individualization of this EBCP is highly recommended.  Due to 
the many potential ethical dilemmas created, the paramount being the moral and ethical 
obligation not to violation the “dead donor rule,” (a donor must not be killed by the harvest of an 
organ) and the requirement that organs be anatomical gifts (that no one may purchase a human 
body organ), there is unsurprisingly much legislation and regulation surrounding the topic (CMS, 
1993).  It is essential to be aware of the laws and regulations surrounding the cDCD process  for 
any change to be appropriate and sustained.   
Laws and Regulations 
The Ohio Administrative Code , states that a hospital intending to procure organs for 
transplant must have an existing contract with their regional OPO, and must have written policies 
and protocols for organ transplantation that address amongst other issues inclusion of the 
primary care physician (PCP), a thorough education of the patient (or their agent), and detailed 
plans for the management of each OP attempt (SOO, 2017).  There may be caveats in the 
contract between the OPO and the health care organization (HCO) as well as within a particular 
state’s laws which must be addressed in order for the implementation to be lawful, though no 
contract may supersede the law.  The Centers for Medicare and Medicaid (CMS) also assist in 
the regulation of this process.  If an HCO is utilizing the Joint Commission (TJC) for deemed 
status, their requirements will be even stricter.  Generally speaking, these requirements include 
the necessity for: a written agreement between the OPO, a tissue bank and the HCO; cooperative 
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interaction between the parties in the review of data regarding the OP rates and program 
successes or failures; that the hospital has a written policy and procedure for its OP attempts; that 
the staff is educated to the technical, ethical, and cultural components of an OP attempt; that 
records are maintained on every attempt; that the hospital and OPO are standardized in their 
approaches to the OP attempts; that all tissues are able to be traced bi-directionally; and that all 
adverse events are investigated by the hospital (CMS, 1993; TJC, 2020).   
Family and Staff Satisfaction & Donation Rates  
 The family is often the agent for the potential cDCD donor at time of consideration for 
OD.  During such an emotionally traumatic time, it is difficult to assure that informed consent is 
occurring.  This consent is essential to the ethical procurement of organs and must be attended.  
Incorporation of the family in the holistic view of the patient, focused and repetitive education, 
and continual assessment of their understanding is key to meeting the ethical obligation of 
informed consent.  Additionally, the concerns that staff may have, whether due to a lack of 
knowledge on cDCD care or a valid crossing of ethical boundaries, may cause significant moral 
distress and lower their support of cDCD (AOPO, AST, ASTS, NATCO, & UNOS, n.d.; 
Berntzen & Bjork, 2014; Dorflinger, Auerbach, & Siminoff, 2012; Ledoux et al., 2014; 
Neidlinger, Gleason, & Cheng, 2013; Philpot, Aranha, Pilcher, & Bailey, 2016; Prins & Human, 
2019; Scott & Quick, 2012; Sidiropoulos et al., 2016; Smith, Leslie, & Wanden, 2015; TJC, 
2004).  It is essential that the staff involved in the education and consent process with the family 
of a potential cDCD donor continually educate to and assess the family’s comprehension of 
ongoing tests, time between decision and withdrawal of life-support treatment (WLST), and 
general expectations to assure that the family ultimately perceives the process of donating their 
loved one’s organs positively (Berntzen & Bjork, 2014; Dorflinger et al., 2012).  Additionally, it 
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is important to affirm with the family and the staff involved in the process that the donor is seen 
as a whole individual, worthy of the highest care possible.  One such method which had 
promising effects on staff and family was the implementation of a short patient-centered 
statement and a fifteen-second moment of silence to honor the donor prior to the WLST 
(Neidlinger et al, 2013; Smith et al., 2015).  One may improve the family’s satisfaction and the 
OP rate by the OPC having a frank conversation about the benefits and basic principles of organ 
donation prior to asking them for a determination of whether to participate (Philpot et al., 2016; 
Prins & Human, 2019).  An important note is that the breakdown of an EBCP process was shown 
to decrease OP rates, and as such a strong, well-incorporated EBCP is essential to sustained OP 
program success (Razdan, Degenholtz, Kahn, & Driessen, 2015).  Additional measures found to 
increase OP rate and family satisfaction included culturally sensitive communication styles, 
which include an individualized reflection of the types of conversation utilized by the potential 
cDCD donor’s family (Scott & Quick, 2012; TJC, 2004).  At its core, cDCD efforts should focus 
on the family patient, if OD is to be successful.   
Comfort Care and Ethical Perspectives  
 There is an ongoing debate about the ethicality and morality of inclusion of pre-mortem 
measures, which yield no benefit to the donor, but may increase the viability of organs procured 
through the cDCD process.  Currently the resounding message is that if these measures are 
employed with an additional, separate consent of the family, they remain ethical (CCM & ETA, 
2017; Sidiropoulos et al., 2016).  Another common concern of staff is the utilization of comfort 
care medications and their potential to hasten death in this population.  Comfort care medications 
(anticipatory utilization of intravenous pain medications such as fentanyl and sedatives such as 
midazolam) do not hasten death when used similarly to levels utilized in end-of-life care 
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(Ledoux et al., 2014; Wind et al., 2012).  It is essential to disseminate this information to staff 
involved in the OP process, as this concern is likely to negatively affect staff perceptions of OP 
attempts, particularly in those who are not as familiar with the dying process.   
Prediction to Death and Warm Ischemic Time  
One of the biggest clinical drivers within the OP attempt in the cDCD population is the 
struggle to maintain organ viability by reduction of the warm ischemic time (WIT), or the time 
between declaration of death and OP.  This is largely attributed to the limited ability to 
accurately predict time to death after WLST.  Studies of the topic are typically of small sample 
size and measure varying factors which may confound results.  The EBCP implements an 
amalgamation of the best current evidence on which clinical factors to observe for the likeliest 
correct prediction of death within 60 or 120 minutes.  The idealized WIT (e.g. 60 versus 120 
minutes) is dependent upon which organ is being procured, but generally speaking it is more 
common for prediction models to utilize the 60 minutes marker, as it encompasses the greatest 
likelihood of procurement of the most viable organs.  Accordingly, this cut-off will be the 
primary focus of this discussion.  The best indication of death within 60 minutes is the necessity 
of controlled mechanical ventilation, particularly when the required 𝐹𝑖𝑂2 is less than or equal to 
fifty percent (AOPO et al., n.d.; Lewis et al., 2003; Munshi et al., 2015; Rabinstein et al., 2012; 
Wind, Snoeijs, & Brugman, 2012).  However, the following indicators also have a reasonable 
prediction of death within 60 minutes and should be considered when in conjunction with the 
former: dependence on pacemaker, ventricular assistive device, inotropic medication or the 
vasopressor norepinephrine; physician opinion of imminent death; Glasgow Coma Scale score of 
less than five while free from the effects of any pertinent sedatives; and a persistent 𝑆𝑎𝑂2 of less 
than or equal to 92 percent (AOPO et al., n.d.; Lewis et al, 2003; Munshi et al., 2015; Rabinstein 
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et al., 2012).  The following indicators in addition to or where duplicated in opposition to the 
afore-mentioned factors have a less reliable, but still notable ability to predict death within 120 
minutes: 𝐹𝑖𝑂2 greater than or equal to 70 percent; absence of cardiovascular comorbidity (AOPO 
et al., Lesieur, Leloup, Gonzalez, & Mamzer, 2014; Wind et al., 2012).  It is important to note 
that in all of these studies, the best sensitivity and specificities noted for any individual or 
combined factors never reached 90 percent (Lewis et al., 2003; Lesieur et al., 2014; Munshi et 
al., 2015; Rabenstein et al., 2012; Wind et al., 2012).  Thus, the accurate prediction to death 
within 60 minutes with the intent of reduction of WIT and thereby increase of viable OP is an 
ongoing pursuit worthy of additional research.  What is consistently true throughout the 
literature, is that an HCO should implement a well-planned, well-structured, individualized, 
consistently utilized EBCP for the procurement of organs in the cDCD population to ensure 
optimal outcomes for all factors mentioned.  
Stakeholders  
Directly Affected.    
 It would be imprudent and indeed short-sighted not to list the potential donors and their 
families first amongst those who are affected by this proposal.  It is essential in the 
standardization of healthcare behaviors, that HCOs and their personnel never lose sight of the 
profound gift these individuals are offering.  They are seeking to create good out of tragedy, and 
anything less than best, evidence-based efforts neglect this sacrifice.  Transplant recipients are 
additionally affected by the process, and as such it is important that the EBCP includes evidence-
supported processes with the likeliest outcome of viable organs that maintains itself within the 
confines of ethical procurement.  Additionally, the primary care physicians, critical care 
intensivists (or their designees who would be performing the determination of death), the OPC, 
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the intensive care nurses who participate in the pre-death care, the OR staff including surgeons 
who participate in the post-mortem procurement, and the staff development department, or 
education department who would be involved in the dissemination of this change in process are 
all directly affected by the implementation of the EBCP.  As such, all efforts should be focused 
on assuring that the concerns of these stakeholders are incorporated into the individualization of 
the EBCP.   
Indirectly Affected.    
 Those indirectly affected, but in greatest position to support or terminate this change 
proposal would be the c-level suite executives.  A primary focus on the key stakeholders Chief 
Nursing Officer and Chief Medical Officer would be prudent, as they are the leaders of the staff 
most affected by the process.  Additionally, the Chief Anesthesiologist would be a key 
stakeholder-informant to the process (CCM & ETA, 2017).  Other potential stakeholders who 
should be included in the initial individualization of the EBCP include: the OPO and OPC; the 
transplant program manager; the hospital’s risk management leader; and any nursing director 
who presides over intensive care units, with particular attention paid to the cardiovascular 
intensive care unit director(s).  These individuals support of or opposition to this change will 
greatly affect the outcome of the implementation.  Thus, it is essential to garner buy-in from 
these groups by allowing them opportunity to provide feedback and champion the components of 
the EBCP most pertinent to their roles.   
Planned Implementation  
Phase One: Research & Development  
The implementation of an EBCP for the cDCD population will follow the foundation of a 
phase-gate project management structure, utilizing the components of the project life cycle to 
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maintain consistent stakeholder interest and participation in the change process.  Each gate will 
be utilized to assure at the end of each phase that the project continues to meet the HCO’s values, 
mission, and goals before continuing on to the next phase.   
Gate 0 is the initial agreement to initiate efforts to improve the cDCD process through the 
utilization of the EBCP.  The initial phase will consist of an evaluation of the stakeholders’ 
perceptions of the current cDCD program and synthesis of the current body of knowledge for 
EBCP utilization for the cDCD population.  The literature review presented herein is the starting 
point from which the HCO should expand its individualized information needs.  A baseline of 
the staff’s current concerns and the facility’s current procedures will assist in illuminating the 
gaps between current practice and best practice.  Identification of the educational needs of the 
HCO is essential in this phase.  For the exemplar Toledo Hospital, educational needs were 
compartmentalized into four main topics: ethical issues surrounding cDCD; the EBCP process; 
family-centered care within the context of a cDCD donor OP attempt including current 
knowledge on comfort care for this population; and regulatory guidelines review for the OP 
process.  The recommendations in this project, therefore reflect these individualized needs and 
while site-specific, also address many of the national topics which are ideally addressed in 
similar sites’ endeavors.  At the end of this phase, all data will be shared with minimally the key 
stakeholders for recommendation of additional educational components and approval to proceed 
through Gate 1 onto Phase 2.   
Phase Two: Plan Individualization  
During this phase, the staff development (education) team will be heavily utilized to 
convert the education topics into staff-friendly education modules, based on the individual 
HCO’s needs.  The pre-test and first of two total post-tests should be created at the time of the 
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education modules.  An example of questions to include in the tests, based upon the exemplar 
hospital is included in the data collection section, following.  However,  the focus of the 
assessment should be on the individual educational needs of the HCO to which this project is 
applied, the staff support of the cDCD process, the EBCP itself, and the ethics of cDCD overall.   
An expert panel including minimally the Chief Anesthesiologist and staff development 
team will review the EBCP proposed and make any recommendations for individualization 
necessary to assure the EBCP will meet the needs of the populations served.  Additionally, the 
panel will make final determinations on which predictive tool will be utilized in the prediction of 
time to death, as few have been externally validated to the degree necessary to have a strong 
evidentiary support (Munshi et al., 2015).  This further requires stakeholder engagement in the 
selection process.  It not only is prudent to include these individuals for their specific knowledge, 
it is an essential component to assuring their buy-in to the change process.  Allowing them to be 
a part of the project at each gate fosters their ownership in the project and provides opportunity 
for those with the most pertinent knowledge to engage in laying the foundation to the project’s 
success.  Gate 2 provides a structured stopping point to confirm the individualization of the 
education and EBCP meets the mission, values and goals of the HCO.   
Phase Three: Education 
During this phase, staff will be educated on the EBCP which was adapted to the 
individual needs of the facility and cDCD population of the HCO’s region during the previous 
phase.  In the exemplar, the education focuses on the afore-mentioned four core issues in 
response to and in anticipation of the greatest barriers to change implementation success.  This 
sub-phase is expected to take two weeks.  Individualization efforts in Phase 2 are reflected here.  
The Toledo Hospital requires education to: the EBCP process, the Centers for Medicare and 
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Medicaid, Ohio Administrative Code, and The Joint Commission laws and regulations governing 
cDCD process; and the ethical foundation of cDCD with a focus on the safety and morality of 
providing comfort care due to their site-specific concerns and hesitations.  A pre-test and initial 
post-test are administered during this phase, immediately before and after the education is 
provided to the staff.  The data collection effort is divided between the HCO and the OPO.  The 
education-based data (test results which include both staff perceptions of the cDCD process as 
well as cDCD facts) are collected by the HCO during this phase.  The OPO will collects data 
related to the clinical success of the implementation of the EBCP and family satisfaction with the 
cDCD process during the next phase, implementation.  OPOs are required by law to collect and 
share certain metrics, discussed in the data collection section, as they are reportable to the 
government.  As such, they are the ideal mechanism through which to collate this data.  The 
progress of the project will be reviewed at Gate 3 and if approved, the project will proceed to 
Phase 4.   
Phase 4: Implementation 
During the implementation phase, the roll-out of the true EBCP project will begin.  When 
a potential cDCD donor is identified, the EBCP will be initiated and utilized by staff to assist in 
the OP attempt.  The EBCP proposed includes space for individualization to family needs, as is 
necessary in all evidence-based projects.  The change champion will monitor outcomes with 
stakeholders in debriefings after each cDCD OP attempt to identify any unforeseen barriers and 
address with the stakeholder team accordingly.  One specific holistic recommendation that is 
included in the education and implementation subphases, but not listed in Addendum A is the 
incorporation of a moment of silence prior to WLST.  Evidence supports this particular modality 
of donor recognition increases family satisfaction with the donation process and a defined 
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structure for donor recognition assists in the reduction of moral distress for staff involved in the 
cDCD OP process (Neidlinger, Gleason, & Cheng, 2013; Smith, Leslie, & Wynaden, 2015).  
Preliminary findings and barriers noted during this phase will be discussed and addressed with 
the stakeholders at Gate 4 before initiation of the final phase, Evaluation. 
Phase 5: Evaluation 
The final phase, Phase 5, will be utilized to evaluate the effectiveness of the 
implementation of an EBCP in the family and staff satisfaction outcomes as well as the OP 
outcomes as compared with the previous baseline.  A final post-test will be administered to 
verify what knowledge the staff retained throughout the change process.  It will be subject to 
some bias, as repeated exposure to the test will increase retention of the material therein.  An 
increase in OP will be an obvious identification of project success, however, increased staff 
willingness to participate in the OP process and continued or improved expressions of family 
satisfaction with the OP process will also mark success for the change project.  It is essential that 
a family-as-patient, holistic mindset be incorporated not only throughout the planning and 
implementation phases of this project, but that it also be employed in the evaluation of any 
process improvement which affects patient family lives.  Data collected will be aggregated, 
contrasted against comparable metrics, and presented to the stakeholders at Gate 5.  This 
terminates the change process and further revisions or performance improvement measures are 
recommended to be addressed in a plan-do-study-act cyclical fashion, with a maximal 
interspacing of annual reviews between cycles. 
Timetable / Flowchart  
 As previously noted, a phased-gate process will be followed to ensure stakeholder 
inovlvement throughout the change process.  (See fig.1)  A minimum of three to four months 
should be utilized in the process to assure an effective transition to the new processes.  The first 
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phase should last approximately two months, and is the longest phase of the 5-phase process.  
This is because a well-researched understanding of the HCO’s local and national laws and 
regulations governing the process must exist if the individualization of the EBCP is to occur in 
the second phase.  It would be important to have the stakeholders identify their common 
concerns such that education needs are identified prior to the second phase, as well.  As is 
common to phase-gate project management, each phase is initiated by a gate, where the 
stakeholders must agree to continue with the process or the project is terminated.  It may seem 
cumbersome or bureaucratic to employ this method, but it is a key component to assure 
continued awareness of the project and agreement to its progress and components by 
stakeholders.  The first gate (Gate 0) was the agreement to undertake this project.  The second 
gate (Gate 1), which lies between Phase 1 and Phase 2, will mark the point at which the 
stakeholders, primarily those indirectly affected, will identify any needs or agree to continue 
with the plan for individualization after receiving a summation of the current data.  Depending 
on ther level of involvement and the HCO’s environment, they may choose to participate in 
Phase 2 in a more direct manner.   
During the second phase, the EBCP and education plans will be individualized to meet 
the HCO’s internal and external boundaries and needs.  This is the second-longest stage of the 
process, because it is the time when the EBCP and education are to be tailored to the prioritized 
focus and organizational constraints specific to the HCO undertaking this process, which is time-
consuming if done properly.  The individualized EBCP should be incorporated into the policy 
and procedure of the organizaton as an appendix to assure its sustained utilization throughout the 
organizatoin.  Once the EBCP has been individualized to meet the abilities of the HCO and to 
assure consistency with the HCO’s mission, values, and goals, it enters the third gate, (Gate 2).  
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It is here that the individualized EBCP is reviewed by the indirectly affected as well as select 
members of the directly affected (e.g. managers of the education department or directors of the 
intensive care units), appropriate to the HCO’s structure, are included in the approval, 
recommendation for revision, or rejection of the project.  This would be the key time to assure 
the approval of the amended policy and procedure document through whathever bodies 
necessary.   
Assuming it is approved to continue, (staff) education is the next phase implemented.  It 
should be rolled out no shorter than over two weeks, though a longer implementation of this 
phase is recommended where possible.  This allows for the individualized EBCP and HCO-
specific needs-focused information is disseminated to the staff.  A pre-test, part of the evaluation 
phase, should be administered prior to the education to help identify what the true baseline of the 
staff was prior to their education.  Additionally, an immediate post-test should be administered 
after the education dissemination.  Please see the evaluation section for more detail on the pre-
test and post-test components, which include subjective and objective assessments.   
The fourth gate (Gate 3) will reflect a review of the pre- and post-test results and a 
sharing of the content included in the education with a focus on the EBCP and how this 
structured, standardized approach is current best evidence to support OP efforts.  The education 
should be tailored to address which topics are of greatest concern to the directly affected 
stakeholders and reflected at this Gate’s review. Once approved, the project would enter the 
Implementation phase, or Phase 4.   
In this phase, the EBCP would be operationalized.  A minimum of a month is 
recommended, due to the relative infrequency of these types of cases.  If six months of data is 
possible to be obtained before progressing to the next gate, it is highly recommended.  Once 
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sufficient data regarding the utilization of the EBCP is achieved (a minimum of 10 attempted 
donations is recommended), the data collected can be evaluated at Gate 4.   
The final phase of the implementation is the evaluation.  A final post-test, a duplicate of 
the initial post-test should be administered at the onset of this phase.  These results should be 
compared against the pre-test and post-test administered in Phase 3, along with metrics 
associated with the OP rates and any family feedback received by managers throughout the 
implementation phase.  It is here that the data is collated, reviewed and preparred for 
dissimination with recommendations for future actions and the initiation of a plan-do-study-act 
cycle should be initiated to sustain improvements in OP rates, family satisfaction, and any other 
key individualizations noted in the plan from Phase 2.  Finally, at Gate 5, the information should 
be disseminatied to all organizationally pertinent stakeholders to show if and to what level the 
EBCP utiliztaion and its corresponding education positively affected OP rates, and staff and 
family satisfaction.  
 
(Figure 1.  Timeline and Flowchart of EBCP Implementation Plan) 
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Data Collection Methods / Planned Evaluation  
Data collection should regard two major components of the project, the education to and 
the effectiveness of the EBCP.  Education outcomes can most readily be collected by the 
utilization of a pre-test, post-test mechanism.  The recommended staff education outcomes to 
measure within this test is a 5-point Likert-scale evaluation of the following topics: level of 
agreement with the ethical and moral stance of OP; and level of agreement with willingness to 
participate in OP practices at the HCO.  More objective measurements that are recommended for 
inclusion, assuming they meet the individualized education of the HCO, include: agreement with 
the statement that comfort care measures do not hasten death; accurate understanding of the 
“dead donor rule;” accurate correlation between the Maastricht III and the cDCD population; 
appropriate manner for escalation of ethical concerns within the hospital; and three key 
indicators for an increased accurate prediction of time to death within 60 minutes, as noted on 
the EBCP.  An improvement in the aggregate from pre-test to first post-test indicates a response 
to the education provided.  An improvement or maintenance of similar aggregate scores between 
the first and second post-test indicates a sustained knowledge retention and reinforcement of key 
principles through the utilization of the EBCP as well as increased organizational involvement in 
the changed process.   
It is standard for certain metrics to be collected by the OPO and shared with the HCO, as 
they are required by federal and many state laws to collect and report these OD-related data.  
They include: donor identification rates (rate the HCO staff identifies a potential donor within 
one hour of meeting the potential donor criteria); donor conversion rates (number of potential 
donors who become organ donors); and OP rate (number of viable organs, skin tissue, eyes, 
etc.…per donor).  It would be prudent, therefore, not to reinvent the wheel in the measurement of 
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the EBCP’s success.  Utilize the baseline data from as many months as the implementation 
covers, prior to the implementation of the EBCP, as a comparison against the data for the 
implementation period.  Any improvements can be attributed to the utilization of and training 
about the EBCP.   
Cost / Benefit Discussion  
Resources  
 Resources are fortunately easily controlled in this change process.  All stakeholders 
mentioned above have agreed to engage in the change process or process improvement attempt 
via the implementation of an EBCP, which they have further agreed to participate in 
individualizing to their facility and populations served.  The staff development department 
within the HCO will be utilized to disseminate education to address current deficiencies in the 
staff understanding of the evidence-based practices and current body of knowledge.  As this 
education is already a legal requirement for any OP facility, it is considered within the existent 
budgetary constraints and labor hours the HCO will incur.  The testing can be administered with 
the education and by the change champion.  Considering the risks of a poor versus excellent 
reputation for OP within the community, it is well worth the relatively minor increase in one 
staff member’s workload.   
Costs 
Currently, the cost of the attempt for OP should rest upon the OPO.  This is a standard 
component of most contracts between OPOs and HCOs, as it is required by law (CMS, 1993; 
SOO, 2017).  As there should be no perceived financial benefit from the ORG in the 
procurement of organs, whose staff is involved in the cDCD donors’ end of life determinations 
and care, the OPO will remain the responsible party for the costs and benefits associated with the 
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procurement of organs.  The costs of the OP program will be negotiated independently of the 
change process between the HCO and the OPO and are outside the scope of this project.  The 
implementation of an EBCP is anticipated to increase efficiency and staff support of the 
program, and as such does not have readily anticipated increases to current costs beyond those 
required to educate staff.  As education to these processes are mandated by regulatory bodies, it 
is not considered an increase to current expenditures, either.  All costs associated with labs or 
diagnostic procedures are paid by the OPO, per current policy.  The donor family is not charged 
for the attempt to procure organs from their loved one, per law (CMS, 1993; SOO, 2017. 
Discussion  
Discussion 
The Coronavirus-19 pandemic swept through the country during the attempted 
implementation of this project, causing a conversion to a benchmark project.  However, key 
lessons learned during this project are reflected herein.  To assure stakeholder buy-in, utilize an 
implementation process such as a phase-gate project management model, which incorporates 
stakeholders into the design.  This encourages all levels of stakeholders feel ownership of the 
change process.  Incorporate the EBCP into the HCO’s policies and procedures.  This engrains it 
into the fabric of the HCO’s processes, assisting in its sustainability.  Education should address 
some basic issues, such as the legal, ethical and logistical components of organ donation in this 
unique population.  Educating staff to the process and surrounding foundation for cDCD helps 
foster their support of cDCD OP attempts, which further supports OP rates, particularly when 
education focuses on appropriate staff interactions with donor families and appropriate use of 
comfort care measures.  However, it must be individualized to the specific HCO’s needs and 
potential biases for or against the process.   
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The use of an EBCP standardizes and thereby structurally supports the ethical boundaries 
and logistic needs of an attempted cDCD OP.  Equitable treatment of all potential donor and 
donor families via a standardized approach also supports the necessary ethical confines of this 
OP process.  The use of an EBCP increases OP rates in an ethical manner that helps meet 
everyone’s ultimate goal of extending transplant recipients’ lives.   
  Finally, it is essential to recognize that timing is integral to any change process.  Read 
the room.  If the HCO is facing severe external constrains on its resources, this may not be the 
best time to implement.  That doesn’t mean it should never occur, but evidence-based practice 
must always have the patient at its core.  If the HCO is not meeting the needs of the patient 
population, it’s not doing its ethical and moral obligation to its community.  Desire to do good 
for one’s community only extends as far as its usefulness to that community.   
Conclusion and Recommendations 
 In summary, the findings of this benchmark project inform the recommendations to use 
an individualized EBCP for OP within the cDCD population.  Incorporate holistic donor family-
patient practices into the EBCP to increase family satisfaction and assure informed consent.  
Education of the staff and donor family are key components to the EBCP’s success. 
Incorporation of the EBCP into the HCO’s policies and procedures further engrains it into the 
HCO’s practices and culture.  Utilization of a phase-gate project management structure for the 
change process supports the sustained involvement of stakeholders to the change process and 
thus increases buy-in.  The end-goal is the facilitation of a meaningful gift between donors and 
families experiencing tremendous tragedy to help avert the same for others.  All reasonable 
measures to maximize the potential of these gifts of time are the ethical and moral obligation of 
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HCOs.  Implementation of an EBCP is a structured, standardized and well-supported mechanism 
to meet this goal.   
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